Salinomycin as a Drug for Targeting Human Cancer Stem Cells

Figure 3

Breast cancer metastasis regression by salinomycin. Orthotopic subcutaneous metastases after mastectomy in a 40-year-old female patient (see Section 7.1. Case  1) with metastatic invasive ductal breast carcinoma, triple negative (estrogen receptor: negative, progesterone receptor: negative, HER2: negative). (a) before, (b) after 12 intravenous administrations of 200 μg·kg⁻¹ salinomycin every second day. Adapted from [104].

(a)

(b)